Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Helio S Sader; Leonard R Duncan; S. J. Ryan Arends; Cecilia G Carvalhaes; Mariana Castanheira

doi:10.1128/AAC.01433-20

Back

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Journal article

Peer reviewed

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Helio S Sader, Leonard R Duncan, S. J. Ryan Arends, Cecilia G Carvalhaes and Mariana Castanheira

Antimicrobial agents and chemotherapy, Vol.64(11), e01433-20

10/20/2020

DOI: 10.1128/AAC.01433-20

PMID: 32900683

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/7577171View

Open Access

Abstract

Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC 50/90 , 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC 50/90 , ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC 50/90 , 0.5/2 mg/liter; 99. ABSTRACT Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC 50/90 , 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC 50/90 , ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC 50/90 , 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at ≤8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of S. maltophilia infections, addressing a major unmet medical need.

Details

Title: Subtitle: Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide
Creators: Helio S Sader - JMI Laboratories
Leonard R Duncan - JMI Laboratories
S. J. Ryan Arends - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Mariana Castanheira - JMI Laboratories
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.64(11), e01433-20
DOI: 10.1128/AAC.01433-20
PMID: 32900683
NLM abbreviation: Antimicrob Agents Chemother
ISSN: 0066-4804
eISSN: 1098-6596
Grant note: DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100004319, name: Pfizer
Language: English
Date published: 10/20/2020
Academic Unit: Microbiology and Immunology; Pathology
Record Identifier: 9984185170102771

Metrics

20 Record Views

31 Times Cited - Web of Science